Nurix Therapeutics CFO Houte Hans van Sells $74.6K of Stock
Houte Hans van, CFO, sold 4,769 shares of Nurix Therapeutics, Inc. at $15.38 to $16.20 a share (average $15.63) in 2 transactions, worth $74.6K in total on Nov 4, 2026. Shares held after the trade: 42,745 (-3.3%).
Nurix Therapeutics CLO Christine Ring Sells $432K of Stock
Christine Ring, CLO, sold 16,715 shares of Nurix Therapeutics, Inc. at $25.74 to $26.76 a share (average $25.84) in 3 transactions, worth $432K in total between Nov 2, 2026 and Nov 3, 2026. Shares held after the trade: 4,406 (-58.1%).
Nurix Therapeutics Deal Termination with Sanofi S.A.
Nurix Therapeutics announced that its collaboration partner Sanofi has decided to discontinue the Phase 1 clinical trial and terminate the SAR448272 oral STAT6 degrader program. As a result, Nurix will no longer be eligible for future development, regulatory, or commercial milestone payments and royalties specifically for this program, though other licensed programs under the Sanofi collaboration remain active.
Nurix Therapeutics CFO Houte Hans van Sells $74.5K of Stock
Houte Hans van, CFO, sold 2,834 shares of Nurix Therapeutics, Inc. at $26.28 a share, worth $74.5K in total on Oct 30, 2026. Shares held after the trade: 47,514 (-5.6%).
Nurix Therapeutics CLO Christine Ring Sells $104K of Stock
Christine Ring, CLO, sold 3,957 shares of Nurix Therapeutics, Inc. at $26.28 a share, worth $104K in total on Oct 30, 2026. Shares held after the trade: 15,335 (-20.5%).
Nurix Therapeutics CSO Gwenn Hansen Sells $143K of Stock
Gwenn Hansen, CSO, sold 5,409 shares of Nurix Therapeutics, Inc. at $26.28 to $26.80 a share (average $26.42) in 2 transactions, worth $143K in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 123,452 (-1.2%).